ImmunityBio (IBRX) Long-Term Investments (2014 - 2026)

ImmunityBio (IBRX) has reported Long-Term Investments for 10 consecutive years, with $891000.0 the latest figure, recorded in Q4 2023.

• In Q4 2023, Long-Term Investments rose 6.07% year-over-year to $891000.0; the TTM figure through Dec 2023 stood at $891000.0 (up 6.07% YoY), while the FY2023 annual figure was $891000.0, up 6.07% from the prior year.
• Long-Term Investments advanced to $891000.0 in Q4 2023 per IBRX's latest filing, from $817000.0 in the prior quarter.
• Across five years, Long-Term Investments topped out at $9.3 million in Q3 2019 and bottomed at $802000.0 in Q3 2021.
• Historically, Long-Term Investments has averaged $3.1 million across 5 years, with a median of $878000.0 in 2022.
• Annual changes were most pronounced in 2019 — Long-Term Investments surged 1221.86% — and 2021, when it sank 91.33%.
• ImmunityBio's Long-Term Investments stood at $9.3 million in 2019, then fell by 15.17% to $7.8 million in 2020, then slumped by 89.53% to $822000.0 in 2021, then advanced by 2.19% to $840000.0 in 2022, then increased by 6.07% to $891000.0 in 2023.
• Business Quant data shows IBRX's Long-Term Investments at $891000.0 in Q4 2023, $817000.0 in Q3 2023, and $841000.0 in Q2 2023.